Author:
Ducreux Michel,Petersen Lone Nørgård,Öhler Leopold,Bergamo Francesca,Metges Jean-Philippe,de Groot Jan Willem,Wang Jaw-Yuan,García Paredes Beatriz,Dochy Emmanuelle,Fiala-Buskies Sabine,Cervantes Andrés,O'Connor Juan Manuel,Falcone Alfredo
Reference18 articles.
1. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity;Wilhelm;Int J Cancer,2011
2. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial;Grothey;Lancet,2013
3. STIVARGA (regorafenib) tablets Prescribing Information,2018
4. STIVARGA (regorafenib) Summary of product characteristics,2018
5. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial;Demetri;Lancet,2013
Cited by
51 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献